Novel Guanidine Compound against Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species
作者:Aamer Saeed、Alejandra Bosch、Marisa Bettiol、Diana Nossa González、Mauricio Erben、Yanina Lamberti
DOI:10.3390/molecules23051158
日期:——
Chronic pulmonary infection is a hallmark of lung disease in cystic fibrosis (CF). Infections dominated by non-fermentative Gram-negative bacilli are particularly difficult to treat and highlight an urgent need for the development of new class of agents to combat these infections. In this work, a small library comprising thiourea and guanidine derivatives with low molecular weight was designed; these derivatives were studied as antimicrobial agents against Gram-positive, Gram-negative, and a panel of drug-resistant clinical isolates recovered from patients with CF. One novel compound, a guanidine derivative bearing adamantane-1-carbonyl and 2-bromo-4,6-difluouro-phenyl substituents (H-BDF), showed potent bactericidal activity against the strains tested, at levels generally higher than those exhibited by tobramycin, ceftazimide and meropenem. The role that different substituents exert in the antimicrobial activity has been determined, highlighting the importance of the halo-phenyl group in the guanidine moiety. The new compound displays low levels of cytotoxicity against THP-1 and A549 cells with a selective index (SI) > 8 (patent application PCT/IB2017/054870, August 2017). Taken together, our results indicate that H-BDF can be considered as a promising antimicrobial agent.
在囊性纤维化(CF)中,慢性肺部感染是肺部疾病的一个标志。由非发酵性革兰氏阴性杆菌主导的感染特别难以治疗,这凸显了迫切需要开发一类新的药物来对抗这些感染。本项工作中,设计了一个小型化合物库,包含一系列低分子量的硫脲和胍衍生物,并将其作为抗菌剂进行研究,对抗来自CF患者的革兰氏阳性菌、革兰氏阴性菌以及一系列耐药临床分离株。其中一种新型化合物,一种带有金刚烷-1-羰基和2-溴-4,6-二氟苯基取代基的胍衍生物(H-BDF),显示出强大的杀菌活性,其程度通常高于妥布霉素、头孢他啶和美罗培南。确定了不同取代基在抗菌活性中的作用,突出了胍部分中的卤代苯基的重要性。这种新型化合物对THP-1和A549细胞显示出较低的细胞毒性,选择性指数(SI)大于8(专利申请PCT/IB2017/054870,2017年8月)。综合来看,我们的结果表明,H-BDF可以被认为是一种有前途的抗菌剂。